MYC and glioma: Finally, ESURATAG-GS exhibit high positive correlation with aging and EMT scores, and MYC-driven targets in 20 different glioma patient datasets (Figure 7F), confirming that MYC-driven ESURATAG-GS lies at the heart of aging-related tumor aggressiveness in glioma patients.